A Phase Ia, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0152, an IAP Protein Antagonist, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs GDC 0152 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 20 Jun 2017 Status changed from completed to discontinued. This study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor activity.
- 18 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2009 New trial record